['diabetes mellitus, type 2']
['empagliflozin 10 mg + linagliptin 5 mg', 'empagliflozin 10 mg', 'empagliflozin 25 mg + linagliptin 5 mg', 'empagliflozin 25 mg', 'placebo']

        Inclusion criteria:

          -  Diagnosis of type 2 diabetes prior to informed consent

          -  Male and female patients on diet and exercise regimen for at least 12 weeks prior to
             informed consent who are:

               -  drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to
                  informed consent or,

               -  pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of
                  the maximum approved dose) on stable dosage for at least 12 weeks prior to the
                  informed consent (for thiazolidinedione, therapy has to be unchanged for at least
                  18 weeks prior to the informed consent). Individual antidiabetic drug will have
                  to be discontinued at Visit 1.

          -  haemoglobin A1c (HbA1c) at Visit 1 (screening)

               -  for patients without antidiabetic therapy : HbA1c >=8.0 to =<10.5%

               -  for patients with one oral antidiabetic drug : HbA1c >=7.5 to =<10.5%

          -  HbA1c >=7.5 to =<10.0% at Visit 4 for randomisation into the double blind treatment
             period

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level >270 mg/dL (>15.0 mmol/L) during the
             open label stabilisation period and placebo run in period

          -  Impaired renal function, defined as estimated glomerular filtration rate (eGFR) <45
             mL/min/1.73m2 (modification of diet in renal disease (MDRD) formula)

          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks
             prior to informed consent

          -  Indication of liver disease, defined by serum levels of either alanine transaminase
             (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper
             limit of normal (ULN)
      